As the United Nations General Assembly’s high-level meeting on antimicrobial resistance (AMR) convenes in New York next week, we urge leaders to prioritize tackling a crucial blind spot: AMR test-to-treat data.
Competing Interests
Table of Contents
M.S. receives funding for studies, advisory board or speaker work from the NIHR, Biomerieux, deePull, Gentian, Roche Diagnostics, Safeguard Biosystems, Volition. R.A.M. is an inventor on the UK patent application number 1814532.6 filed by University College London Business. C.S.B. does occasional ad hoc one-off market research advisory consultations – solely through market research companies (Sermo, Atheneum, M3). R.A.M. and C.S.B. are investigators for the EPSRC Digital Health Hub for AMR, for which Roche, Faculty, AWS, Arup and Microsoft are partners.